Meropenem therapy failure in Listeria monocytogenes infection

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Listeria monocytogenes is a significant human pathogen, causing listeriosis, particularly in immunocompromised individuals.
• Meropenem exhibits potent in vitro activity against Listeria monocytogenes.
• Clinical data on meropenem's efficacy in treating listeriosis are limited.

Observation:

• A child with aplastic anemia developed nosocomial Listeria monocytogenes infection.
• Initial treatment with meropenem for 5 days did not resolve fever and was associated with clinical worsening.
• The patient's condition improved after the addition of ampicillin to the treatment regimen.

Findings:

• Meropenem monotherapy may be insufficient for treating severe Listeria monocytogenes infections in certain clinical contexts.
• Clinical response to meropenem in listeriosis can be variable and may not correlate with in vitro susceptibility.
• Combination therapy, including ampicillin, may be crucial for effective treatment of complex listeriosis cases.

Implications:

• This case highlights the potential limitations of meropenem in treating clinical listeriosis, even with demonstrated in vitro susceptibility.
• The findings suggest that established treatment guidelines for listeriosis, often involving ampicillin, should be carefully considered.
• Further research is warranted to elucidate the mechanisms behind meropenem treatment failure and to optimize therapeutic strategies for Listeria monocytogenes infections.